Scope of application of the ursodeoxycholic acid at gastroenterological pathology
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 2
Abstract
The article presents modern concepts on the using of ursodeoxycholic acid in the clinical practice of internist. The presented review is focused on the effects of ursodeoxycholic acid, the current spectrum of it’s application in the treatment of the patients with gastroenterological pathology, in particular, gastroesophageal reflux disease, non-alcoholic fatty liver disease, autoimmune hepatobiliary processes, chronic hepatitis, intestinal dysbiosis. The literature review has covered the historical data on the release of ursodeoxycholic acid, the first studies on the results of this drug using, and listed the ursodeoxycholic acid effects and scope of application. The literature review presents data from the global studies of the ursodeoxychloric acid effects on patients with the above listed nosology. The efficacy of its preparation has been proved in terms of reduction of the clinical manifestations of intrahepatic cholestasis in pregnant women without side effects. The presented data showed the survival prolongation in patients with primary biliary cholangitis against the background of ursodeoxychloric acid administration. It has been emphasized that long-term use of ursodeoxycholic acid at viral hepatitis, along with etiotropic therapy, allowed to eliminate the clinical manifestations and to avoid the development of complications. It was demonstrated that ursodeoxycholic acid has protective properties against the damaging effect of bile acids on the esophagus walls at gastroesophageal reflux disease. The data have been presented on the UCDA positive effects on the lipid spectrum in patients with non-alcoholic fatty liver disease. The data illustrating the significant positive differences in the composition and function of the microbiome after prolonged use of ursodeoxycholic acid have been outlined.
Authors and Affiliations
L. V. Zhuravlyova, O. V. Ogneva
The results of multicenter study of efficacy of Helicobacter pylori eradication therapy, conducted according to the recommendations of Maastricht V Consensus Report
Objective — to study efficacy and safety of two weeks quadruple therapy with high doses of pantoprazole, bismuth subcitrate, clarithromycin, amoxicillin with concomitant adjuvant symbiotic therapy (Saccharomyces boulardi...
Adenomak — new possibilities in a hepatotherapy
-
The role of intestinal microbiome in the progression of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is considered an important and economically significant public health problem, its progression can result in development of cirrhosis and hepatocellular carcinoma. Over the past...
Pathogenetic role of visceral adipose tissue in the development of non-alcoholic fatty liver disease in patients with metabolic syndrome
Objective — to study the nature of changes in carbohydrate and lipid metabolism, depending on the distribution and activity of visceral adipose tissue (VAT), and the degree of liver steatosis in patients with nonalcoholi...
Clinical Practice Guidelines of European Association for the Study of the Liver (EASL) on nutrition in chronic liver disease. Part 2
-